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Abstract. In the current study, arrhythmogenic effects of the 
gap junction inhibitor heptanol (0.05 mM) were examined 
in Langendorff-perfused mouse hearts. Monophasic action 
potential recordings were obtained from the left ventricular 
epicardium during right ventricular pacing. Regular activity 
was observed both prior and subsequent to application of 
heptanol in all of the 12 hearts studied during 8 Hz pacing. By 
contrast, induced ventricular tachycardia (VT) was observed 
after heptanol treatment in 6/12 hearts using a S1S2 protocol 
(Fisher's exact test; P<0.05). The arrhythmogenic effects of 
heptanol were associated with increased activation latencies 
from 13.2±0.6 to 19.4±1.3 msec (analysis of variance; P<0.001) 
and reduced conduction velocities (CVs) from 0.23±0.01 
to 0.16±0.01 msec (analysis of variance; P<0.001) in an 
absence of alterations in action potential durations (ADPs) 
at x=90% (38.0±1.0 vs. 38.3±1.8 msec), 70% (16.8±1.0 vs. 
19.5±0.9 msec), 50% (9.2±0.8 vs. 10.1±0.6 msec) or 30% 
(4.8±0.5 vs. 6.3±0.6 msec) repolarization (APDx) or in effec-
tive refractory period (ERPs) (39.6±1.9 vs. 40.6±3.0 msec) (all 
P>0.05). Consequently, excitation wavelengths (λ; CV x ERP) 
were reduced from 9.1±0.6 to 6.5±0.6 mm (P<0.01), however 
critical intervals for re-excitation (APD90 - ERP) were unal-
tered (-1.1±2.4 vs. -2.3±1.8 msec; P>0.05). Together, these 
observations demonstrate for the first time, to the best of our 
knowledge, that inhibition of gap junctions alone using a low 
heptanol concentration (0.05 mM) was able to reduce CV, 
which alone was sufficient to permit the induction of VT using 
premature stimulation by reducing λ, which therefore appears 
central in the determination of arrhythmic tendency.
Introduction
An orderly spread of action potentials through the heart is 
critical for normal electrical function and its disruption can 
lead to cardiac arrhythmias (1). Experiments in pre-clinical 
models have advanced understanding of the electrophysi-
ological mechanisms underlying arrhythmogenesis using 
genetic and pharmacological approaches (1-24). Experiments 
in mouse models have highlighted the role of gap junctions 
in ventricular conduction and arrhythmogenesis, however the 
results have been controversial. Heterozygous Cx43+/- mice 
were demonstrated to exhibit at 45-50% reduction in Cx43 
expression, however, the degree of conduction velocity (CV) 
slowing was variable: CV was either unchanged (25-30) or 
reduced by 23-44% (31-33). Additional experiments used 
a pharmacological approach, demonstrating ventricular 
arrhythmogenesis associated with reduced CV using 2 mM 
heptanol (7). This agent inhibits gap junctions specifically at 
concentrations up to 1-2 mM (34,35) however at ≥2 mM addi-
tionally inhibits sodium channels (34,36). The extent to which 
the conduction defects and arrhythmogenesis observed could 
be attributed to loss of gap junction coupling alone remains to 
be fully elucidated.
Therefore, the aims of the present study were to examine the 
possible role of abnormal gap junction function in ventricular 
arrhythmogenesis, by applying heptanol at a low concentra-
tion that specifically targets gap junctions (0.05 mM). At this 
concentration, it was identified that heptanol did not elicit 
spontaneous arrhythmias during regular pacing, however 
increased the incidence of ventricular tachycardia induced by 
a S1S2 protocol. This was associated with increased activation 
latencies in an absence of alterations in either action poten-
tial durations (APDs) or effective refractory periods (ERPs). 
The observations of the present study suggest that loss of gap 
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junction function alone is sufficient to produce conduction 
slowing and ventricular arrhythmogenesis.
Materials and methods
Solutions. The experiments described in this study 
used Krebs-Henseleit solution (composition in mM: 
NaCl 119, NaHCO3 25, KCl 4, KH2PO4 1.2, MgCl2 1, 
CaCl2 1.8, glucose 10 and sodium pyruvate 2; pH 7.4) that 
had been bicarbonate-buffered and bubbled with 95% O2/5% 
CO2 (37). Heptanol (0.82 g ml-1; Sigma-Aldrich, Haverhill, 
UK) is soluble in aqueous solutions up to 9 mM (https://www.
rsc.org/merck-index), and was diluted using Krebs-Henseleit 
solution to produce a final concentration of 0.05 mM.
Preparation of Langendorff‑perfused mouse hearts. A total of 
13 wild-type mice of genetic background 129 (5 and 7 months 
of age, 3 male, 10 female; weight, 39.2±1.9 g) were used in the 
current study. The animals were maintained at room tempera-
ture (21±1˚C) and were subjected to a 12:12 h light/dark cycle 
with free access to sterile rodent chow and water in an animal 
facility. The experiments described here were compliant with 
the UK Animals (Scientific Procedures) Act 1986. The present 
study was approved by the Animal Welfare and Ethical 
Review Body at University of Cambridge. (Cambridge, UK) 
The procedures for the preparation of Langendorff-perfused 
mouse hearts were as follows: Mice were sacrificed by 
cervical dislocation in accordance with Sections 1 (c) and 
2 of Schedule 1 of the UK Animals (Scientific Procedures) 
Act 1986. The hearts were rapidly excised and immediately 
submerged in ice-cold Krebs-Henseleit solution. Cannula-
tion of the aorta was achieved using a tailor-made 21-gauge 
cannula that had been prefilled with ice‑cold buffer. Using a 
micro-aneurysm clip (Harvard Apparatus, Cambridge, UK), 
the heart was securely attached to the perfusion system. Retro-
grade perfusion was initiated at a rate of 2-2.5 ml min-1 using a 
peristaltic pump (Model 505S Bredel Pump; Watson-Marlow, 
Ltd., Falmouth, UK) with the perfusate passing through 
200 and 5 µm filters successively, and heated to 37˚C using 
a water jacket and circulator prior to reaching the aorta. 
The hearts that regained their pink colour and spontaneous 
rhythmic activity were studied further (approximately 90%). 
The remaining 10% were discarded. Perfusion took place for 
a further 20 min to minimise any residual effects of catechol-
amine released endogenously, prior to electrophysiological 
analysis of the hearts.
Stimulation protocols. Electrical stimulation was achieved 
using paired platinum electrodes (1 mm interpole distance) 
placed at the right ventricular epicardium. This took place 
at 8 Hz, using square wave pulses 2 msec in duration, with a 
stimulation voltage set to three times the diastolic threshold 
(Grass S48 Square Pulse Stimulator; Grass-Telefactor; Astro 
Med, Inc., Slough, UK) immediately subsequent to the start 
of perfusion. The S1S2 protocol was used to assess arrhyth-
mogenicity and identify re-entrant substrates. This consisted 
of a drive train of 8 regularly paced S1 stimuli separated by a 
125 msec basic cycle length (BCL), followed by premature S2 
extra stimuli every ninth stimulus. The S1S2 interval was first 
set to 125 msec and then successively reduced by 1 msec with 
each nine stimulus cycles until arrhythmic activity was initi-
ated or refractoriness was reached, whereupon the S2 stimulus 
elicited no ventricular response.
Recording procedures. Monophasic action potential (MAP) 
recordings from the left ventricular epicardium were obtained 
using a MAP electrode (Linton Instruments; Harvard Appa-
ratus). MAPs from the left ventricular endocardium were 
obtained using a custom-made MAP electrode that was made 
from two strands of 0.25 mm Teflon‑coated silver wire (99.99% 
purity; Advent Research Materials, Ltd., Witney, UK). To 
eliminate direct current offset, the electrode tips were galvani-
cally chlorided. The stimulating and recording electrodes 
were maintained at constant positions, with an inter-electrode 
distance of 3 mm. This allowed CVs to be determined from 
the activation latencies. All recordings were performed using 
a BCL of 125 msec (8 Hz) to exclude rate-dependent differ-
ences in APDs. MAPs were pre‑amplified using a NL100AK 
head stage, amplified with a NL104A amplifier and band 
pass filtered between 0.5 Hz and 1 kHz using a NL125/6 
filter (Neurolog; Digitimer, Ltd., Welwyn Garden City, UK) 
and then digitized (1401plus MKII; Cambridge Electronic 
Design, Ltd., Cambridge, UK) at 5 kHz. They were then 
analysed using Spike2 version 5.11 software (Cambridge Elec-
tronic Design, Ltd.). MAP waveforms that did not match the 
previous established stringent criteria for MAP signals were 
rejected (38). They must have stable baselines, fast upstrokes, 
with no inflections or negative spikes, and a rapid first phase of 
repolarization. 0% repolarization was measured at the peak of 
the MAP and 100% repolarization was measured at the point 
of return of the potential to baseline (38-40).
The following parameters were obtained from the 
experimental records: i) Activation latency, defined as the 
time difference between the stimulus and the peak of the 
MAP; ii) CV, as the ratio of the inter-electrode distance to the 
activation latency. As the latter distance was kept constant, 
CVs were inversely proportional to the corresponding acti-
vation latencies; iii) APDx, the time difference between the 
peak of the MAP and x=30, 50, 70 and 90% repolarization; 
iv) ERP, defined as the longest S1S2 interval at which the S2 
extra stimulus failed to initiate a ventricular signal during 
programmed electrical stimulation; v) excitation wavelength, 
λ, given by CV x ERP; vi) critical intervals for re-excitation 
given by APD90 - ERP.
Statistical analysis. All values are expressed as the 
mean ± standard error. Categorical data were compared with 
Fisher's exact test (one-tailed) using OriginPro version 8 
(OriginLab Corporation, Northampton, MA, USA). Different 
experimental groups were compared by one-way analysis of 
variance. P<0.05 was considered to indicate a statistically 
significant difference. P<0.05, 0.01 and 0.001 were denoted by 
*, ** and ***, respectively.
Results
Ventricular arrhythmogenicity and its association with action 
potential activation and recovery properties were examined 
prior and subsequent to introduction of 0.05 mM heptanol 
in Langendorff-perfused mouse hearts. The right ventricular 
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epicardium was electrically stimulated using either regular 
8 Hz or S1S2 pacing (2,3,5,7,12). MAP recordings were 
obtained from the left ventricular epicardium. The stimu-
lating and recording electrodes were maintained at a constant 
distance of 3 mm, which permitted CVs to be estimated from 
the respective activation latencies. Ventricular tachycardia 
(VT) was defined as a series of ≥5 action potentials with 
coupling intervals closer than the BCL.
Heptanol at 0.05 mM exerts ventricular pro‑arrhythmic effects 
during S1S2, however not during regular pacing. The initial 
experiments conducted during regular pacing demonstrated 
consistent ventricular activity in the absence of spontaneous 
arrhythmias in all of the 12 hearts studied, whether prior or 
subsequent to introduction of 0.05 mM heptanol, or following 
removal of heptanol from the perfusate (Fig. 1). The second 
set of experiments then applied a S1S2 pacing protocol, which 
imposed extra systolic S2 stimuli following trains of regular S1 
pacing stimuli. The S1S2 interval was initially at the BCL and 
subsequently reduced by 1 msec with each cycle until the S2 
stimuli produced either arrhythmic activity or refractoriness. 
The latter indicating that the ERP was reached. None of the 
hearts studied demonstrated evidence of inducible arrhythmias 
prior to application of the test agent (Fig. 2A). By contrast, it 
was possible to induce VT subsequent to application of heptanol 
(Fig. 2B). The incidences of inducible VT prior and subsequent 
to introduction of heptanol, and following its withdrawal from 
the perfusing solution are summarized in Fig. 2C, indicating 
that heptanol exerted significant pro‑arrhythmic effects, as the 
extra stimuli were able to induce VT in 6/12 hearts (*P<0.05; 
Fisher's exact test).
Pro‑arrhythmic effects of heptanol were associated with reduced 
CVs in an absence of alterations in APDs or ERPs. Previous 
studies in mouse models have associated increased arrhythmo-
genicity with reduced CVs, prolonged or shortened APDs and 
reduce ERPs (2,3,5,7,12). These values were therefore obtained 
from the experimental recordings described above. Thus, heptanol 
increased activation latencies from 13.2±0.6 to 19.4±1.3 msec 
(Fig. 3A; analysis of variance; P<0.001) and reduced CVs from 
0.23±0.01 to 0.16±0.01 msec (Fig. 3B; P<0.001), without altering 
APD90 (38.0±1.0 vs. 38.3±1.8 msec; Fig. 3C), APD70 (16.8±1.0 
vs. 19.5±0.9 msec; Fig. 3D), APD50 (9.2±0.8 vs. 10.1±0.6 msec; 
Fig. 3E), APD30 (4.8±0.5 vs. 6.3±0.6 msec; Fig. 3F) or ERPs 
(39.6±1.9 vs. 40.6±3.0 msec; Fig. 3G).
Pro‑arrhythmic effects of heptanol were associated with 
reduced excitation wavelengths despite unaltered critical inter‑
vals. Reductions in excitation wavelengths (λ; CV x ERP) and 
increases in critical intervals for re-excitation (APD90 - ERP) 
have been associated with increased arrhythmogenicity (7,41). 
Accordingly, these parameters were calculated for the 
hearts used in the current study. Heptanol reduced λ from 
9.1±0.6 to 6.5±0.6 mm (Fig. 4A; P<0.01) without altering 
critical intervals (-1.1±2.4 vs. -2.3±1.8 msec; Fig. 4B).
Discussion
Sudden cardiac death (SCD) is a significant problem and is 
responsible for around 60,000 deaths in the UK (42), 200,000 
deaths in the US (43) and 4-5 million deaths globally (44) 
per year. It has been suggested that SCD arises from the 
development of malignant ventricular arrhythmias, the 
electrophysiological mechanisms of which remain to be 
fully understood. Mouse hearts have been used to study 
arrhythmogenesis as they are amenable to both genetic and 
pharmacological manipulation.
Figure 1. Stable MAPs obtained during regular 8 Hz pacing (A) prior to 
and (B) subsequent to introduction of 0.05 mM heptanol. MAP, monophasic 
action potential.
Figure 2. (A) Refractory outcomes observed prior to the introduction of the 
test agent and (B) the induced ventricular tachycardia following introduc-
tion of 0.05 mM Hep during S1S2 pacing. (C) Number of hearts showing 
refractory (clear bar) or arrhythmic (black bar) outcomes. *P<0.05 vs. control. 
Hep, heptanol; MAP, monophasic action potential.
  A
  B
  A
  B
  C
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Propagation of the action potentials through the working 
myocardium depends on sodium channel activation followed 
by gap junction conduction. Gap junctions are hexameric 
proteins made of connexins mediate intercellular coupling 
by allowing passive electrotonic spread of ions and of larger 
molecules (45). Their resistance contributes to axial resis-
tance and modulates CV (46,47). Cx43 is the isoform present 
in ventricles, and the effects of loss of Cx43 on ventricular 
conduction and arrhythmogenesis have been extensively 
studied in mouse models (25-33,48,49), however, with signifi-
cant disagreement between the results of these studies (28). 
Thus, cardiac-restricted Cx43 inactivation followed by 
crossing with Cre recombinase produced mosaic mice, in 
which Cx43 was observed to be educed by up to 95% when 
compared with wild-type mice (48). Additional experiments 
identified that heterozygous Cx43+/- mice exhibited a 45-50% 
reduction in Cx43 expression. In these mice, CV was either 
unchanged (25-30) or reduced by 23-44% (31-33). These 
studies suggest different parameters, including interstitial 
volume (50), width of the perinexus, intracellular calcium 
concentrations, perfusate composition and osmolarity (28), 
have additional effects on cardiac conduction. Pharmacolog-
ical methods have additionally been used to study the role of 
gap junctions in arrhythmogenesis. A previous study reported 
that 2 mM heptanol exerted significant pro-arrhythmic 
effects by reducing CVs without influencing APDs, however 
increased ERPs (7). These alterations led to reduced excita-
tion wavelength (λ; CV x ERP), which is consistent with the 
increased likelihood of re-entry. Heptanol is an agent that 
reversibly inhibits gap junctions at concentrations up to 1 mM 
and also sodium channels at concentrations ≥2 mM (34,36). It 
was therefore not possible to determine the relative contribu-
tions of gap junction uncoupling vs. reduced sodium channel 
function in the reduction of CV and the ventricular arrhythmo-
genesis observed. Furthermore, 2 mM heptanol produced not 
only CV slowing, however additionally increased ERPs. The 
latter observation is consistent with its effects on sodium 
channel kinetics of producing a depolarizing shift of the acti-
vation curve, and a hyperpolarizing shift of the inactivation 
curve, which would reduce the sodium window current (36). 
Increasing ERP alone is suggested to be anti-arrhythmic via 
the increase in λ, regional increases in ERP could theoreti-
cally predispose to re-entry by producing refractory obstacles 
Figure 3. Hep (0.05 mM) increased (A) activation latencies and (B) reduced CV values without affecting APD values at (C) 90%, (D) 70%, (E) 50% or (F) 30% 
repolarization (APDx), or (G) ERPs. ***P<0.001; Hep, heptanol; CV, conduction velocity; APD, action potential duration; ERP, effective refractory period.
Figure 4. Hep (0.05 mM) (A) reduced excitation wavelengths (λ; CV x ERP), 
(B) without altering critical intervals for re-excitation (CI, APD90 - ERP). 
**P<0.01 vs. control. Hep, heptanol; CV, conduction velocity; ERP, effective 
refractory period. 
  A   B   C
  D   E   F
  G
  A
  B
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around which action potentials can circulate, and areas of 
unidirectional conduction block (51).
Therefore, the present experiments were conducted to 
determine whether heptanol at a concentration that specifi-
cally inhibits gap junctions (0.05 mM) (34,36) could produce 
pro-arrhythmic effects. Its application resulted in an increased 
incidence of inducible, however not spontaneous, arrhythmias, 
which was associated with increased activation latencies and 
reduced CVs, in an absence of alterations in APDs or ERPs. 
Together, these alterations led to a reduced excitation wavelength 
(λ) despite leaving critical intervals unaltered. These results are 
consistent with previous observations that inhibition of gap 
junctions and sodium channels at 2 mM heptanol resulted in a 
greater degree of CV slowing compared with the low concentra-
tion used in the current study, and increased ERPs. Under these 
conditions, spontaneous and provoked VT were observed. In 
the present study, gap junction inhibition alone using 0.05 mM 
heptanol did not elicit spontaneous VT during regular pacing.
As the aim of this study was to examine the effects of 
reducing gap junction coupling, it was therefore appropriate to 
use the MAP method. This method has been extensively used 
to study cardiac electrophysiology in animal systems (8,52-59). 
For future experiments, the measurement of magnetic signals 
may be beneficial. It has been previously demonstrated to useful 
for characterizing cardiac structural abnormalities (60-62), 
and observed that functional mapping could be achieved using 
magnetocardiography in mouse models. Thus, it is suggested 
that its use in assessing abnormal cardiac electrophysiology in 
mice warrants future investigation (63-66).
In conclusion, the current study demonstrated that gap junc-
tion inhibition by heptanol alone was sufficient to reduce CV 
without affecting APD or ERP, and the consequent reduction 
in λ was suggested to be responsible for the arrhythmogenesis 
observed.
Acknowledgements
Dr Gary Tse was awarded a BBSRC Doctoral Training Award 
from the University of Cambridge (Cambridge, UK).
References
 1. Tse G: Both transmural dispersion of repolarization and 
transmural dispersion of refractoriness are poor predictors of 
arrhythmogenicity: A role for the index of Cardiac Electrophysi-
ological Balance (QT/QRS)? J Geriatr Cardiol, 2016.
 2. Tse G, Tse V and Yeo JM: Ventricular anti-arrhythmic effects of 
heptanol in hypokalaemic, Langendorff-perfused mouse hearts. 
Biomed Rep 4: 313-324, 2016. 
 3. Tse G, Tse V, Yeo JM and Sun B: Atrial anti-arrhythmic effects 
of heptanol in Langendorff-perfused mouse hearts. PLoS One 11: 
e0148858, 2016.
 4. Tse G: Mechanisms of cardiac arrhythmias. J Arrhythm 32: 
75-81, 2016. 
 5. Tse G, Wong ST, Tse V and Yeo JM: Restitution analysis 
of alternans using dynamic pacing and its comparison 
with S1S2 restitution in heptanol-treated, hypokalaemic 
Langendorff-perfused mouse hearts. Biomed Rep 4: 673-680, 
2016.
 6. Tse G and Yeo JM: Conduction abnormalities and ventricular 
arrhythmogenesis: The roles of sodium channels and gap 
junctions. Int J Cardiol Heart Vasc 9: 75-82, 2015. 
 7. Tse G, Hothi SS, Grace AA and Huang CL: Ventricular arrhyth-
mogenesis following slowed conduction in heptanol-treated, 
Langendorff-perfused mouse hearts. J Physiol Sci 62: 79-92, 
2012.
 8. Tse G, Wong ST, Tse V and Yeo JM: Monophasic action potential 
recordings: Which is the recording electrode? J Basic Clin 
Physiol Pharmacol, 2016. 
 9. Tse G, Lai TH, Yeo JM, Tse V and Wong SH: Mechanisms 
of electrical activation and conduction in the gastrointestinal 
system: Lessons from cardiac electrophysiology. Front Physiol 7: 
182, 2016.
10. Tse G, Wong ST, Tse V and Yeo JM: Depolarization vs. repolar-
ization: What is the mechanism of ventricular arrhythmogenesis 
underlying sodium channel haploinsufficiency in mouse hearts? 
Acta Physiol (Oxf), 2016. 
11. Chen Z, Sun B, Tse G, Jiang J and Xu W: Reversibility of both 
sinus node dysfunction and reduced HCN4 mRNA expression 
level in an atrial tachycardia pacing model of tachycardia-brady-
cardia syndrome in rabbit hearts. Int J Clin Exp Pathol 9, 2016.
12. Tse G, Sun B, Wong ST, Tse V and Yeo JM: Ventricular 
anti-arrhythmic effects of hypercalcaemia treatment in 
hyperkalaemic, Langendorff-perfused mouse hearts. Biomed 
Rep 4:313-324, 2016.
13. Tse G, Lai ET, Tse V and Yeo JM: Molecular and electrophysi-
ological mechanisms underlying cardiac arrhythmogenesis in 
diabetes mellitus. J Diabetes Res, 2016. (In press)
14. Tse G, Wong ST, Tse V and Yeo JM: Determination of action 
potential wavelength restitution in Scn5a+/- mouse hearts 
modelling human Brugada syndrome. J Physiol, 2016. (In press)
15. Osadchii OE: Flecainide-induced proarrhythmia is attributed 
to abnormal changes in repolarization and refractoriness in 
perfused guinea-pig heart. J Cardiovasc Pharmacol 60: 456-466, 
2012.
16. Osadchii OE: Quinidine elicits proarrhythmic changes in 
ventricular repolarization and refractoriness in guinea-pig. Can J 
Physiol Pharmacol 91: 306-315, 2013.
17. Wilde AA, Postema PG, Di Diego JM, Viskin S, Morita H, 
Fish JM and Antzelevitch C: The pathophysiological mechanism 
underlying Brugada syndrome: Depolarization versus repolar-
ization. J Mol Cell Cardiol 49: 543-553, 2010.
18. Osadchii OE: Impact of hypokalemia on electromechanical 
window, excitation wavelength and repolarization gradients in 
guinea-pig and rabbit hearts. PLoS One 9: e105599, 2014.
19. Osadchii OE: Impaired epicardial activation-repolarization 
coupling contributes to the proarrhythmic effects of hypoka-
laemia and dofetilide in guinea pig ventricles. Acta Physiol 
(Oxf) 211: 48-60, 2014.
20. Hsieh YC, Lin JC, Hung CY, Li CH, Lin SF, Yeh HI, Huang JL, 
Lo CP, Haugan K, Larsen BD and Wu TJ: Gap junction modifier 
rotigaptide decreases the susceptibility to ventricular arrhythmia 
by enhancing conduction velocity and suppressing discordant 
alternans during therapeutic hypothermia in isolated rabbit 
hearts. Heart Rhythm 13: 251-261, 2016.
21. Hsieh YC, Lin SF, Huang JL, Hung CY, Lin JC, Liao YC, 
Lo CP, Wang KY and Wu TJ: Moderate hypothermia (33˚C) 
decreases the susceptibility to pacing‑induced ventricular fibril-
lation compared with severe hypothermia (30˚C) by attenuating 
spatially discordant alternans in isolated rabbit hearts. Zhonghua 
Minguo Xin Zang Xue Hui Za Zhi 30: 455-465, 2014.
22. Hsieh YC, Lin SF, Lin TC, Ting CT and Wu TJ: Therapeutic 
hypothermia (30 degrees C) enhances arrhythmogenic substrates, 
including spatially discordant alternans, and facilitates 
pacing‑induced ventricular fibrillation in isolated rabbit hearts. 
Circ J 73: 2214-2222, 2009.
23. Choy L, Yeo JM, Tse V, Chan SP and Tse G: Cardiac disease and 
arrhythmogenesis: Mechanistic insights from mouse studies. Int 
J Cardiol Heart Vasc 12: 1-10, 2016. 
24. Tse G, Lai ET, Chan YWF, Yeo JM and Yan BP: What is the 
arrhythmic substrate in viral myocarditis? Insights from clinical 
and animal studies. Front Physiol 7: 308, 2016.
25. Stein M, van Veen TA, Remme CA, Boulaksil M, Noorman M, 
van Stuijvenberg L, van der Nagel R, Bezzina CR, Hauer RN, 
de Bakker JM and van Rijen HV: Combined reduction of inter-
cellular coupling and membrane excitability differentially affects 
transverse and longitudinal cardiac conduction. Cardiovasc 
Res 83: 52-60, 2009.
26. Stein M, van Veen TA, Hauer RN, de Bakker JM and 
van Rijen HV: A 50% reduction of excitability but not of inter-
cellular coupling affects conduction velocity restitution and 
activation delay in the mouse heart. PLoS One 6: e20310, 2011.
27. Morley GE, Vaidya D, Samie FH, Lo C, Delmar M and Jalife J: 
Characterization of conduction in the ventricles of normal 
and heterozygous Cx43 knockout mice using optical mapping. 
J Cardiovasc Electrophysiol 10: 1361-1375, 1999.
TSE et al:  GAP JUNCTION INHIBITION, CONDUCTION VELOCITY AND VENTRICULAR ARRHYTHMOGENESIS4074
28. George SA, Sciuto KJ, Lin J, Salama ME, Keener JP, Gourdie RG 
and Poelzing S: Extracellular sodium and potassium levels 
modulate cardiac conduction in mice heterozygous null for the 
Connexin43 gene. Pflugers Arch 467: 2287-2297, 2015. 
29. Vaidya D, Tamaddon HS, Lo CW, Taffet SM, Delmar M, 
Morley GE and Jalife J: Null mutation of connexin43 causes slow 
propagation of ventricular activation in the late stages of mouse 
embryonic development. Circ Res 88: 1196-1202, 2001.
30. van Rijen HV, Eckardt D, Degen J, Theis M, Ott T, Willecke K, 
Jongsma HJ, Opthof T and de Bakker JM: Slow conduction and 
enhanced anisotropy increase the propensity for ventricular 
tachyarrhythmias in adult mice with induced deletion of 
connexin43. Circulation 109: 1048-1055, 2004.
31. Guerrero PA, Schuessler RB, Davis LM, Beyer EC, Johnson CM, 
Yamada KA and Saffitz JE: Slow ventricular conduction in mice 
heterozygous for a connexin43 null mutation. J Clin Invest 99: 
1991-1998, 1997.
32. Thomas SA, Schuessler RB, Berul CI, Beardslee MA, Beyer EC, 
Mendelsohn ME and Saffitz JE: Disparate effects of deficient 
expression of connexin43 on atrial and ventricular conduction: 
Evidence for chamber-specific molecular determinants of 
conduction. Circulation 97: 686-691, 1998.
33. Eloff BC, Lerner DL, Yamada KA, Schuessler RB, Saffitz JE 
and Rosenbaum DS: High resolution optical mapping reveals 
conduction slowing in connexin43 deficient mice. Cardiovasc 
Res 51: 681-690, 2001.
34. Christ GJ, Spektor M, Brink PR and Barr L: Further evidence 
for the selective disruption of intercellular communication by 
heptanol. Am J Physiol 276: H1911-H1917, 1999. 
35. Rüdisüli A and Weingart R: Electrical properties of gap junction 
channels in guinea-pig ventricular cell pairs revealed by exposure 
to heptanol. Pflugers Arch 415: 12-21, 1989.
36. Nelson WL and Makielski JC: Block of sodium current by 
heptanol in voltage-clamped canine cardiac Purkinje cells. Circ 
Res 68: 977-983, 1991.
37. Balasubramaniam R, Grace AA, Saumarez RC, Vandenberg JI and 
Huang CL: Electrogram prolongation and nifedipine-suppressible 
ventricular arrhythmias in mice following targeted disruption of 
KCNE1. J Physiol 552: 535-546, 2003.
38. Knollmann BC, Katchman AN and Franz MR: Monophasic 
action potential recordings from intact mouse heart: Vali-
dation, regional heterogeneity, and relation to refractoriness. 
J Cardiovasc Electrophysiol 12: 1286-1294, 2001.
39. Gussak I, Chaitman BR, Kopecky SL and Nerbonne JM: Rapid 
ventricular repolarization in rodents: Electrocardiographic 
manifestations, molecular mechanisms, and clinical insights. 
J Electrocardiol 33: 159-170, 2000.
40. Fabritz L, Kirchhof P, Franz MR, Eckardt L, Mönnig G, 
Milberg P, Breithardt G and Haverkamp W: Prolonged action 
potential durations, increased dispersion of repolarization, and 
polymorphic ventricular tachycardia in a mouse model of proar-
rhythmia. Basic Res Cardiol 98: 25-32, 2003.
41. Wiener N and Rosenblueth A: The mathematical formulation of 
the problem of conduction of impulses in a network of connected 
excitable elements, specifically in cardiac muscle. Arch Inst 
Cardiol Mex 16: 205-265, 1946.
42. Implantable cardioverter defibrillators for arrhythmias. Review 
of technology appraisal 11. National Institute for Health and 
Clinical Excellence (NICE), 2007.
43. Adabag AS, Luepker RV, Roger VL and Gersh BJ: Sudden 
cardiac death: Epidemiology and risk factors. Nat Rev Cardiol 7: 
216-225, 2010.
44. Chugh SS, Reinier K, Teodorescu C, Evanado A, Kehr E, 
Al Samara M, Mariani R, Gunson K and Jui J: Epidemiology of 
sudden cardiac death: Clinical and research implications. Prog 
Cardiovasc Dis 51: 213-228, 2008.
45. Spray DC and Burt JM: Structure-activity relations of the cardiac 
gap junction channel. Am J Physiol 258: C195-C205, 1990. 
46. Dhillon PS, Gray R, Kojodjojo P, Jabr R, Chowdhury R, Fry CH 
and Peters NS: Relationship between gap-junctional conductance 
and conduction velocity in mammalian myocardium. Circ 
Arrhythm Electrophysiol 6: 1208-1214, 2013.
47. Peters NS: Gap junctions: Clarifying the complexities of 
connexins and conduction. Circ Res 99: 1156-1158, 2006.
48. Gutstein DE, Morley GE, Tamaddon H, Vaidya D, Schneider MD, 
Chen J, Chien KR, Stuhlmann H and Fishman GI: Conduction 
slowing and sudden ar rhythmic death in mice with 
cardiac-restricted inactivation of connexin43. Circ Res 88: 
333-339, 2001.
49. Beauchamp P, Choby C, Desplantez T, de Peyer K, Green K, 
Yamada KA, Weingart R, Saffitz JE and Kléber AG: Electrical 
propagation in synthetic ventricular myocyte strands from 
germline connexin43 knockout mice. Circ Res 95: 170-178, 
2004.
50. Veeraraghavan R, Salama ME and Poelzing S: Interstitial 
volume modulates the conduction velocity-gap junction rela-
tionship. Am J Physiol Heart Circ Physiol 302: H278-H286, 
2012.
51. Hondeghem LM: QTc prolongation as a surrogate for 
drug-induced arrhythmias: Fact or fallacy? Acta Cardiol 66: 
685-689, 2011. 
52. Vigmond EJ: The electrophysiological basis of MAP recordings. 
Cardiovasc Res 68: 502-503, 2005.
53. Vigmond EJ and Leon LJ: Electrophysiological basis of 
mono-phasic action potential recordings. Med Biol Eng 
Comput 37: 359-365, 1999.
54. Tse G: Novel conduction‑repolarization indices for the stratifi-
cation of arrhythmic risk. J Geriatr Cardiol, 2016. (Accepted)
55. Tse G: (Tpeak-Tend)/QRS and (Tpeak-Tend)/(QT x QRS): Novel 
markers for predicting arrhythmic risk in Brugada syndrome. 
Europace, 2016. (Accepted)
56. Tse G and Yan BP: Novel arrhythmic risk markers incorpo-
rating QRS dispersion: QRSd x (Tpeak-Tend)/QRS and QRSd 
x (Tpeak-Tend)/(QT x QRS). Ann Noninvasive Electrocardiol, 
2016. (Accepted).
57. Tse G, Lai ET, Yeo JM and Yan BP: Electrophysiological mech-
anisms of Bayés syndrome: Insights from clinical and mouse 
studies. Front Physiol 7: 188, 2016.
58. Tse G, Lai ET, Lee AP, Yan BP and Wong SH: Electrophysi-
ological mechanisms of gastrointestinal arrhythmogenesis: 
Lessons from the heart. Front Physiol 7, 2016.
59. Tse G, Wong ST, Tse V and Yeo JM: Variability in local action 
potential durations, dispersion of repolarization and wave-
length restitution in aged wild-type and Scn5a+/- mouse hearts 
modelling human Brugada syndrom. J Geriatr Cardiol, 2016. 
(Accepted)
60. Tse G, Ali A, Alpendurada F, Prasad S, Raphael CE and 
Vassiliou V: Tuberculous constrictive pericarditis. Res 
Cardiovasc Med 4: e29614, 2015.
61. Tse G, Ali A, Prasad SK, Vassiliou V and Raphael CE: Atypical 
case of post-partum cardiomyopathy: An overlap syndrome with 
arrhythmogenic right ventricular cardiomyopathy? BJR|case 
reports 1: 20150182, 2015.
62. Vassiliou V, Chin C, Perperoglou A, Tse G, Ali A, Raphael C, 
Jabbour A, Newby D, Pennell D, Dweck D and Prasad S: 
93 ejection fraction by cardiovascular magnetic resonance 
predicts adverse outcomes post aortic valve replacement. 
Heart 100: A53-A54, 2014.
63. Ono Y and Ishiyama A: Non-invasive cardiac functional 
mapping on disease-model mice-development of high spatial 
resolution SQUID system for MCG on mice. Teion Kogaku 40: 
44-50, 2005.
64. Tse G and Yan BP: Traditional and novel ECG conduction and 
repolarization markers of sudden cardiac death. Europace, 2016. 
(In press).
65. Tse G, Yan BP, Chan YW, Tian XY and Huang Y: Reactive 
oxygen species, endoplasmic reticulum stress and mitochondrial 
dysfunction: the link with cardiac arrhythmogenesis. Front 
Physiol 7: 313, 2016. 
66. Hu Z, Chen Z, Wang Y, Jiang J, Tse G, Xu W, Ge J and Sun B: 
Effects of granulocyte colony-stimulating factor on rabbit carotid 
and swine heart models of chronic obliterative arterial disease. 
Mol Med Rep, 2016. (Accepted).
